Lifeline Biotechnologies Inc (LLBO)

[MEAD II]

IMO once LLBO passes the development phase and moves on to the market with a product that will prove to be a game-changer in early breast cancer detection.

It will save lives and make a positive difference for so many women worldwide. What is more, we are still in the early stages of the life of this technology which may offer one explanation for the limited interest, or so it seems at this point in time.

The FDA Clinical Trials are scheduled for completion in February 2017. With that opinion stated, I believe that patient investors will be rewarded with a price per share between .15 and .20.

As of this writing, the estimated pps is .053 as noted on this site and I do not think that the buyout price is unreasonable once lights go green. IMHO/LLBO LONG GLTA